Both in Biotechnology
Monte Rosa Therapeutics vs Ginkgo Bioworks Holdings
Over the past year GLUE returned −13.8% and DNA returned −15.9%; their daily moves had a correlation of 0.18.
GLUE −13.8% DNA −15.9%Growth of $1, one year, split-adjusted
| Metric | GLUE | DNA |
|---|---|---|
| Price | $10.41 | $10.76 |
| Market cap | $888.1M | $724.6M |
| Today | −2.07% | +9.24% |
| 1 month | +1.4% | −28.2% |
| 6 months | −46.2% | +10.8% |
| Year to date | −33.6% | +29.5% |
| 1 year | −19.0% | −17.2% |
| Revenue growth (YoY) | −61.3% | −48.5% |
| Gross margin | 100.0% | 91.5% |
| Net margin | −483.9% | −231.7% |
| P/E (TTM) | — | — |
| Price / sales | 30.9× | 6.5× |
| Net cash | $621.1M | $302.2M |
| Dividend yield | — | — |
| Volatility (60d) | 52.5% | 128.2% |
| Short % of float | 41.9% | 18.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).